

National Drug Formulary

User Guide

Overview

Features of NDF

- Page 3 [Home page](#)
- Page 4 [A-Z Listing, Listing by Pharmacological Class](#)
- Page 5 [Compare Drugs](#)

Conducting Search

- Page 6 [Conducting search using general search function](#)
- Page 7 [A-Z Listing to search for active ingredients by alphabet](#)
- Page 9 [Conducting search using advanced search function](#)

Monograph Page

- Page 10 [Overview of monograph page](#)
- Page 11 [General Information- Drug Page Heading, Subsidy Information and Financing Scheme](#)
- Page 12 [General Information- Drug Guidance for Subsidy](#)
- Page 13 [General Information- Post Marketing Issues, General Availability](#)
- Page 14 [Product Specific Information](#)
- Page 15 [Product Specific Information- Clinical Information](#)
- Page 16 [Product Specific Information- Product Information](#)

Features of NDF

General Search

Search by active ingredient, product name or indication in the basic search bar or use the advanced search or compare drug option.

The screenshot shows the NDF website interface. At the top, there are navigation links: ABOUT US, ABOUT DRUGS, FAQs, and USEFUL RESOURCES. The main header features the NDF logo and the Ministry of Health Singapore logo. Below the header is a search bar with a dropdown menu for letters A-Z and a search button. The search bar is highlighted with a yellow box. Below the search bar are buttons for 'Pharmacological Classification', 'Advanced Search', and 'Compare Drugs'. The 'Advanced Search' button is highlighted with a yellow box. The main content area includes a banner for 'The National Drug Formulary' with icons for 'CLINICAL INFORMATION', 'ACCESSIBILITY', and 'DRUG TERMINOLOGY'. Below the banner is a grid of links under the heading 'National Drug Formulary (NDF)'. The footer contains links for 'Report Vulnerability', 'Privacy Policy', 'Terms of Use', and 'Contact Us', along with copyright information for 2021.

Advanced Search Button
Use advanced search to apply filters and narrow your search option

Features of NDF

The screenshot shows the NDF website's search interface. At the top, there are navigation links for 'ABOUT US', 'ABOUT DRUGS', 'FAQS', and 'USEFUL RESOURCES'. The 'Search for Drug' section includes a search bar with the placeholder text 'Enter Active Ingredient, Product Name or Indications' and a 'Show All' button highlighted in yellow. Below the search bar, there are buttons for 'Pharmacological Classification', 'Advanced Search', and 'Compare Drugs'. The main content area displays 'A to Z Listing' with 'Showing 1 - 50 of 1271 results'. A grid of active ingredients is shown, including Acridinium, Adalimumab, Acetaminophen, and many others. A yellow arrow points from the 'Show All' button to a callout box.

NDF A-Z Listing
Displays active ingredients in alphabetical order



The screenshot shows the NDF website's search interface with the 'Pharmacological Classification' button highlighted in yellow. Below the search bar, there are buttons for 'Advanced Search' and 'Compare Drugs'. The main content area displays 'Listing of Pharmacological Classifications' with a 'Collapse all' option. A list of classifications is shown, including 'A: Alimentary Tract and Metabolism' and 'A03: Drugs for functional gastrointestinal disorders'. A specific classification, 'A03AA: Synthetic anticholinergics, esters with tertiary amino group', is highlighted with a yellow box. A yellow arrow points from this box to a callout box.

NDF Listing by Pharmacological Class
Displays active ingredients based on WHO's ATC classification

Features of NDF

2 Key in active ingredient into search box

1 **Compare Drug**
 Compare drug function allows users to view side by side comparison of general drug information of 2 active ingredients



Conducting search using general search function

List of monographs containing search term. Select desired result to view the **Monograph Page**. Please see the details of Monograph Page from Slide 11 onwards.

List of Products containing the word 'Metformin' as the active ingredients, brand names and/or stated within clinical indication. Select desired result to view the Monograph Page of the product.

The screenshot shows a search bar with the text 'Metformin' entered. Above the search bar is a navigation menu with letters A through Z and a 'Show All' button. Below the search bar are buttons for 'Pharmacological Classification', 'Advanced Search', and 'Compare Drugs'. A yellow rectangular box highlights the search bar, and a yellow arrow points from the right side of the box to a callout box.

Key in search term in the general search bar

Showing 19 results of 95 results based on search terms of "Metformin"

Monographs related to 'Metformin'	
Canagliflozin + Metformin	Active Ingredient
Dapagliflozin + Metformin	Active Ingredient
Empagliflozin + Metformin	Active Ingredient
Glibenclamide + Metformin	Active Ingredient
Linagliptin + Metformin	Active Ingredient
Metformin	Active Ingredient
Products related to 'Metformin'	
ACTOS TABLET 15 MG	Product Name
Active Ingredient: PIOGLITAZONE	
ACTOS TABLET 30 MG	Product Name
Active Ingredient: PIOGLITAZONE	
ADIMET XR TABLET 1000MG	Product Name
Active Ingredient: METFORMIN HYDROCHLORIDE	
ADIMET XR TABLET 500MG	Product Name
Active Ingredient: METFORMIN HYDROCHLORIDE	
ADIMET XR TABLET 750MG	Product Name
Active Ingredient: METFORMIN HYDROCHLORIDE	

A-Z Listing to search for active ingredients by alphabet

2

A to Z Listing

Showing 1 - 50 of 50 results

R

- Rabeprazole
- Rabies Vaccine []
- Racecadotril
- Radium (223-Ra) Dichloride
- Raloxifene
- Raltegravir
- Ramipril []
- Ramucirumab []
- Ranibizumab []
- Ranitidine
- Ranolazine
- Rasagiline
- Rasburicase []
- Regorafenib
- Remdesivir
- Remifentanyl
- Repaglinide
- Resorcinol []
- Revefenacin
- Rhubarb []
- Ribavirin
- Ribociclib
- Rifampicin
Synonym: Rifampin (USAN)
- Rifapentine
- Rifaximin
- Rilpivirine []
- Riluzole
- Riociguat
- Ripasudil
- Risankizumab []
- Risdiplam
- Risedronic Acid
Synonym: Risedronic Acid (INN)
- Risperidone
- Ritonavir []
- Rituximab []
 - Rituximab [Mabthera]
 - Rituximab [Rixathon]
 - Rituximab [Truxima®]
- Rivaroxaban
- Rivastigmine
- Rocuronium
- Romiplostim []
- Romozosumab []
- Ropinirole
- Ropivacaine
- Rosuvastatin
- Rotavirus Vaccine []
- Roxithromycin
- Rubella Vaccine []
- Rufinamide
- Rupatadine

1



- ABOUT US ▾
- ABOUT DRUGS ▾
- FAQS
- USEFUL RESOURCES ▾
- Q



Search for Drug

- A B C D E F G H I J K L M N O P Q **R** S T U V W X Y Z Show All

Enter Active Ingredient, Product Name or Indications



Advanced Search Compare Drugs

Biologics and biosimilars will have a landing page to allow users to compare the general information such as subsidy information, drug guidance for subsidy and post marketing issues for all biologics and biosimilars under Rituximab (See next slide)

**Biologic Landing Page
(available for biological active ingredients with more than 1 brand)**

The landing page allows you to compare the general information such as subsidy information, drug guidance for subsidy and post marketing issues across all Rituximab brands.

Select one of the monographs to view information specific to the product

The screenshot shows a web page for Rituximab with the following sections:

- Subsidy Information and Financing Scheme**:
 - SDI** Rituximab Biosimilar (Truxima) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL
 - MSL** Rituximab (Mabthera) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL. For cancer treatment.
 - MSL** Rituximab (Mabthera) Solution For Subcutaneous Injection 1,400 mg/11.7 mL. 1) Rituximab (subcutaneous) in combination with cyclophosphamide, doxorubicin, vincristine and pred... [See all](#)
 - MSL** Rituximab Biosimilar (Truxima) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL. For cancer treatment.
 - MSL** Rituximab (Rixathon) Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL. For cancer treatment.
- Drug Guidance for Subsidy**:
 - [04/01/2022 Update of MOH List of Subsidised Drugs to include treatments for various cancer conditions](#). The Ministry of Health's Drug Advisory Committee has reviewed all available treatments for can... [See all](#)
 - [18/01/2021 Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis](#). The Ministry of Health's Drug Advisory Committee has recommended:
 - Baricitinib 2 mg and 4 mg t... [See all](#)
 - [18/01/2021 Rituximab for treating non-Hodgkin's lymphoma and chronic lymphocytic leukaemia](#). The Ministry of Health's Drug Advisory Committee has recommended:
 - Rituximab biosimilar (Trux... [See all](#)
- Post Marketing Information**:
 - [DHCP10/07/2013 Communication on updated recommendations for management of hepatitis B reactivation in patients treated with MabThera® \(rituximab\)](#)
 - [DHCP108/02/2013 Communications on the association of MabThera® \(Rituximab\) with Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome](#)
 - [DHCP106/05/2011 Communication on the association of MabThera® \(Rituximab\) with fatal infusion related reactions in patients with Rheumatoid arthritis](#)
- General Availability in Public Healthcare Institution**:
 - *Disclaimer* Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
- List of monographs containing this active ingredient**:
 - [Rituximab \[Mabthera\]](#)
 - [Rituximab \[Rixathon\]](#)

Conducting search using advanced search function

Insert inputs to at least 1 of the mandatory fields and select additional filters to narrow down search results

Advanced Search

Please fill in at least one of the fields

Containing

Any of these words

Active Ingredient(s)

Metformin

Product Name

Product Name

Registration Number

Registration Number

Pharmacological Classification

Pharmacological Classification

Indication

Indication (e.g Diabetes treatment)

Licence Holder

Licence Holder

Country of Manufacturer

Country of Manufacturer

Additional Filters (optional)

Drug Guidance

Yes

SG Specific Post Marketing Issue

Select

Subsidy Info

Subsidy Info

Forensic Classification

Forensic Classification

Reset

Search

1

2

The screenshot shows the NDF search results page. At the top, there is a navigation bar with 'ABOUT US', 'ABOUT DRUGS', 'FAQS', and 'USEFUL RESOURCES'. Below this is the 'Search for Drug' section with a search bar containing 'Metformin' and a search button. The search results show 'Metformin' as the active ingredient. The page also includes a 'Pharmacological Classification' dropdown, 'Advanced Search', and 'Compare Drugs' buttons. At the bottom, there is a pagination control showing 'First < 1 > Last'.

Results shows a list of results with “Metformin” as active ingredient which has relevant drug guidance. Clicking on it brings you to the monograph page.

NDF Monograph Page – Overview

Overview

The drug page will display the drug related information according to the active ingredient(s). This page contains:

A. General information

- Subsidy information
- Drug Guidances
- Post marketing issues
- General Availability in PHI
- Additional information

B. Product specific information

- Clinical information (Indication, dosing and contraindication) (if available)
- Product Information
 - Active Ingredient(s), strength and dosage form
 - Forensic Classification
 - License Number
 - License Holder
 - ATC codes

i icon
Provides more information on the field

A. General Information

B. Product specific information

The screenshot shows the NDF Monograph Page for Rivastigmine. The page is titled 'Rivastigmine' and has a navigation bar with links for 'ABOUT US', 'ABOUT DRUGS', 'FAQS', and 'USEFUL RESOURCES'. The main content is organized into several sections:

- General Information:** Contains 'Subsidy Information and Financing Scheme' (with an 'i' icon highlighted by a yellow box), 'Drug Guidance for Subsidy', 'Post Marketing Information', and 'General Availability in Public Healthcare Institution'.
- Registered Product(s) Information:** This section is expanded to show two categories: 'ORAL' and 'TRANSDERMAL'. Each category has a search bar and a list of products with their respective SIN numbers.

The 'ORAL' section lists products like 'EXELON CAPSULE 1.5 MG [SIN10035P]', 'EXELON CAPSULE 3 MG [SIN10036P]', 'EXELON CAPSULE 4.5 MG [SIN10037P]', and 'EXELON CAPSULE 6 MG [SIN10038P]'. The 'TRANSDERMAL' section lists 'EXELON PATCH 10 (9.5MG/24HR) [SIN13451P]'.

Monograph page- General Information

Drug Page Heading

This shows name of active ingredient (with brand name for biologic/biosimilar) Synonyms if available will appear here as well

Home > A to Z Listing > Rivastigmine

Active Ingredient

Rivastigmine

General Information

Subsidy Information and Financing Scheme ⓘ —

MAF Rivastigmine Transdermal Patch 4.6 mg/24 hr, 9.5 mg/24 hr, 13.3 mg/24 hr

1) Rivastigmine patch formulation (4.6 mg/24 hr and 9.5 mg/24 hr) for the treatment of moderately s...

[See all](#)

Drug Guidance for Subsidy ⓘ —

[05/02/2018 Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease](#)

The Ministry of Health's Drug Advisory Committee has recommended:

- Rivastigmine patch formulation (...)

[See all](#)

Subsidy Information and Financing Scheme

Information on MOH drug subsidies and schemes as shown below, can be found here.

Indicator	Legend
SDL	Standard Drug List
MAF	Medication Assistance Fund
SVL	Subsidised Vaccine List
MSHL	Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List

Monograph page- General Information

The screenshot shows a monograph for Rivastigmine. A pop-up window titled "05/02/2018 Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease" is open. The pop-up contains the following text:

The Ministry of Health's Drug Advisory Committee has recommended:

- Rivastigmine patch formulation (4.6mg/24h and 9.5mg/24h) for the treatment of moderately severe dementia, and behavioural symptoms of dementia, associated with Parkinson's disease.
- Rivastigmine patch formulation (4.6mg/24h, 9.5mg/24h and 13.3mg/24h) for the treatment of moderately severe dementia, and behavioural symptoms of dementia, associated with Alzheimer's disease.

Conditions should be confirmed by a specialist physician (geriatrician, neurologist or psychiatrist) with experience in the treatment of dementia.

Treatment should be continued only when it is considered to be having a worthwhile effect on cognitive, global, functional or behavioural symptoms.

Subsidy status

- R** Rivastigmine patch formulation (4.6mg/24h, 9.5mg/24h and 13.3mg/24h) is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications.
- R** Rivastigmine should be used in line with the clinical criteria in the MAF checklist for initial and continuing prescriptions. Treatment effect has to be re-assessed 6-monthly before further MAF assistance is granted for additional prescriptions.
- NR** MAF assistance does not apply to rivastigmine capsules (1.5mg, 3mg, 4.5mg and 6mg).

The pop-up window also features a yellow-bordered button labeled "Drug Guidance for Subsidy" with an information icon.

Drug Guidance for Subsidy

These are ACE drug guidance related to subsidy information. Users can click on the hyperlink to view the full guidance.

- Drugs that are recommended for subsidy are indicated with **R**
- Drugs that are NOT recommended for subsidy are indicated with **NR**

Monograph page- General Information

Post Marketing Issues

reflects the URL hyperlinks of related Dear Healthcare Professional Letters and Educational materials from HSA

General Availability

is to indicate the availability of the drugs in PHI formulary. They will be reflected according to strength and dosage form (and brand for biologic/biosimilar).

Post Marketing Information ⓘ

[DHCPL 11/05/2010 Inappropriate use of and medication errors associated with Exelon® Patch \(rivastigmine transdermal patch\)](#)

General Availability in Public Healthcare Institution ⓘ

**Disclaimer* Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration*

Transdermal Patch 4.6 mg/24 hr

- Alexandra Hospital
- Changi General Hospital
- Institute of Mental Health
- Khoo Teck Puat Hospital
- Ng Teng Fong General Hospital
- National University Hospital
- Sengkang General Hospital
- Singapore General Hospital
- SingHealth Polyclinics
- Tan Tock Seng Hospital

Transdermal Patch 9.5 mg/24 hr

- Alexandra Hospital
- Changi General Hospital
- Institute of Mental Health
- Khoo Teck Puat Hospital
- Ng Teng Fong General Hospital
- National University Hospital
- Sengkang General Hospital
- Singapore General Hospital
- SingHealth Polyclinics
- Tan Tock Seng Hospital

Transdermal Patch 13.3 mg/24 hr

- Changi General Hospital
- Institute of Mental Health
- Khoo Teck Puat Hospital
- Singapore General Hospital
- Tan Tock Seng Hospital

Capsule 1.5 mg

- Alexandra Hospital
- Changi General Hospital
- Institute of Mental Health
- Khoo Teck Puat Hospital
- National University Hospital
- Singapore General Hospital
- Tan Tock Seng Hospital

Capsule 3 mg

- Alexandra Hospital
- Changi General Hospital
- Institute of Mental Health
- Khoo Teck Puat Hospital
- Ng Teng Fong General Hospital
- National University Hospital
- Singapore General Hospital
- Tan Tock Seng Hospital

Capsule 4.5 mg

- Alexandra Hospital
- Changi General Hospital
- Institute of Mental Health
- Khoo Teck Puat Hospital
- Ng Teng Fong General Hospital
- National University Hospital
- Singapore General Hospital
- Tan Tock Seng Hospital

**Monograph page-
Product specific
Information**

**Registered
Products**

Select a product under the relevant route of administration (e.g. oral) to view the clinical and/or product information of the product.

Registered Product(s) Information

ORAL —

Select a brand starting with the letter:

E

[EXELON CAPSULE 1.5 MG \[SIN10035P\]](#)

[EXELON CAPSULE 3 MG \[SIN10036P\]](#)

[EXELON CAPSULE 4.5 MG \[SIN10037P\]](#)

[See all](#)

TRANSDERMAL —

Select a brand starting with the letter:

E

[EXELON PATCH 10 \(9.5MG/24HR\) \[SIN13451P\]](#)

[EXELON PATCH 15 \(13.3MG/24HR\) \[SIN14500P\]](#)

[EXELON PATCH 5 \(4.6MG/24HR\) \[SIN13450P\]](#)

[Clinical Info](#) ⓘ [Product Info](#) ⓘ

Please select a product for clinical info:

- [EXELON CAPSULE 1.5 MG \[SIN10035P\]](#)
- [EXELON CAPSULE 3 MG \[SIN10036P\]](#)
- [EXELON CAPSULE 4.5 MG \[SIN10037P\]](#)
- [EXELON CAPSULE 6 MG \[SIN10038P\]](#)
- [EXELON PATCH 10 \(9.5MG/24HR\) \[SIN13451P\]](#)
- [EXELON PATCH 15 \(13.3MG/24HR\) \[SIN14500P\]](#)
- [EXELON PATCH 5 \(4.6MG/24HR\) \[SIN13450P\]](#)

Drugs with available clinical information will be listed in the 'Clinical Info' tab

Monograph page- Product specific Information

The screenshot displays a monograph page for EXELON PATCH 10 (9.5MG/24HR) [SIN13451P]. The page is divided into two main sections: a left sidebar for product selection and a main content area for clinical information.

Left Sidebar:

- ORAL** (collapsed)
- Select a brand starting with the letter: **E**
- [EXELON CAPSULE 1.5 MG \[SIN10035P\]](#)
- [EXELON CAPSULE 3 MG \[SIN10036P\]](#)
- [EXELON CAPSULE 4.5 MG \[SIN10037P\]](#)
- [See all](#)
- TRANSDERMAL** (collapsed)
- Select a brand starting with the letter: **E**
- 1 Selected Product** (highlighted)
- [EXELON PATCH 10 \(9.5MG/24HR\) \[SIN13451P\]](#)
- [EXELON PATCH 15 \(13.3MG/24HR\) \[SIN14500P\]](#)
- [EXELON PATCH 5 \(4.6MG/24HR\) \[SIN13450P\]](#)

Main Content Area:

- Clinical Info** (selected) | **Product Info**
- EXELON PATCH 10 (9.5MG/24HR)** [SIN13451P] [Download below as PDF](#)
- Indication** (collapsed)
- INDICATIONS**
- Patch 5, 10 & 15**
Symptomatic treatment of mild to moderately severe, and severe Alzheimer's dementia.
- Patch 5 & 10**
Symptomatic treatment of mild to moderate dementia associated with Parkinson's disease. It is generally recommended to those patients in whom the administration of oral Exelon capsules is unsuitable or infeasible.
- Dosing** (+)
- Contraindications** (+)

2**Clinical Info**

After selecting a product, you will be able to see the indications, dosing and contraindications for the drug under the clinical info tab. Click on “+” to expand the information.

Clinical information are extracted from the Product Inserts or Patient Information Leaflets available on HSA Infosearch.

**Monograph
page- Product
specific
Information**

Registered Product(s) Information

ORAL —

Select a brand starting with the letter:

E

[EXELON CAPSULE 1.5 MG \[SIN10035P\]](#)

[EXELON CAPSULE 3 MG \[SIN10036P\]](#)

[EXELON CAPSULE 4.5 MG \[SIN10037P\]](#)

[See all](#)

TRANSDERMAL —

Select a brand starting with the letter:

E

[EXELON PATCH 10 \(9.5MG/24HR\) \[SIN13451P\]](#)

[EXELON PATCH 15 \(13.3MG/24HR\) \[SIN14500P\]](#)

[EXELON PATCH 5 \(4.6MG/24HR\) \[SIN13450P\]](#)

Clinical Info ⓘ **Product Info ⓘ**

EXELON PATCH 10 (9.5MG/24HR)
[SIN13451P]

Active Ingredient and Strength	RIVASTIGMINE (AS BASE) 18 MG/10 CM ²
Dosage Form	PATCH, EXTENDED RELEASE
Manufacturer and Country	LTS LOHMANN THERAPIE-SYSTEME AG GERMANY
Registration Number	SIN13451P
Licence Holder	NOVARTIS (SINGAPORE) PTE LTD
Forensic Classification	PRESCRIPTION ONLY MEDICINES
Anatomical Therapeutic Chemical (ATC) code	N06DA03

[Download below as PDF](#)

Click on product info tab for product specific info such as license number for the selected product.

Click on 'Download below as PDF' to save or print a copy.